Member access

4-Traders Homepage  >  Shares  >  Amex  >  CEL-SCI Corporation       US1508374097

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases.The company's lead investigational therapy, Multikine, is being developed as a potential therapeutic agent... 
More about the company
Financials ($)
Sales 2014 0,25 M
EBIT 2014 -24,8 M
Net income 2014 -22,9 M
Debt 2014 -
Yield 2014 -
Sales 2015 0,26 M
EBIT 2015 -26,9 M
Net income 2015 -27,0 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 288x
Capi. / Sales 2015 272x
Capitalization 70,8 M
More Financials
Latest news on CEL-SCI CORPORATION
3d ago ERGOMED : Provides Update on Co-Development Partnerships
5d ago CEL SCI : University of Minnesota's Masonic Cancer Center to Join Phase III Head..
09/11 CEL-SCI CORPORATION : Valuation Analysis for CEL-SCI
09/11 CEL SCI : Valuation Analysis for CEL-SCI
09/10 CEL SCI : NEW STORY University of Minnesota Masonic Cancer Center Joins CEL-SCI'..
09/10 CEL SCI : University of Minnesota Masonic Cancer Center Joins CEL-SCI’s Ph..
09/03 CEL SCI : NEW STORY CEL-SCI Enrolls 20 Patients in August in Its Phase III Immun..
09/03 CEL SCI : Enrolls 20 Patients in August in Its Phase III Immunotherapy Head and ..
08/19 CEL SCI : NEW STORY CEL-SCI Expands its Global Phase III Immunotherapy Head and ..
08/19 CEL SCI : Expands its Global Phase III Immunotherapy Head and Neck Cancer Trial ..
08/12 CEL-SCI CORPORATION : Potential Payoffs Spur Big Board Biotech Action
08/08 CEL SCI : NEW STORY CEL-SCI Corporation Reports Third Quarter Fiscal 2014 Financ..
More news
Comments 
Advertisement
Income Statement Evolution
CEL-SCI Corporation : Income Statement Evolution
More Financials
EPS Revisions
CEL-SCI Corporation : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF